8 hedge funds and family offices disclose a CVS position in their latest SEC 13F filing — combined $1.94B in market value. Of those, 2 are classified as value investors.
| # | Investor | Fund | Shares | Value | % of Portfolio | Filed |
|---|---|---|---|---|---|---|
| 1 | Christopher Davis | Davis Selected Advisers, LP | 11,865,916 | $1.23B | 5.27% | 2026-06-30 |
| 2 | Viking Global | Viking Global Investors LP | 3,663,361 | $379.0M | 1.08% | 2026-06-30 |
| 3 | Prem Watsa | Fairfax Financial Holdings Ltd | 2,712,000 | $280.5M | 10.63% | 2026-06-30 |
| 4 | Ray Dalio | Bridgewater Associates LP | 440,972 | $45.6M | 0.19% | 2026-06-30 |
| 5 | Mark Hillman | Hillman Capital Management Inc | 71,685 | $5.7M | 3.58% | 2025-12-31 |
| 6 | Matrix Asset Advisors | Matrix Asset Advisors Inc/NY | 6,175 | $490K | 0.04% | 2025-12-31 |
| 7 | Christopher Bloomstran | Semper Augustus Investments Group LLC | 499 | $40K | 0.01% | 2025-12-31 |
| 8 | Olstein Capital Management | Olstein Capital Management LP | 56,000 | $4K | 0.91% | 2025-12-31 |
As of the latest 13F window, 8 tracked superinvestors hold CVS. The largest disclosed position is Christopher Davis at $1.23B (5.3% of portfolio).
13F filings are due 45 days after each quarter end and capture long-equity positions held by U.S. institutional managers with $100M+ AUM. Use this page to see exactly who is buying CVS, how concentrated each position is, and the implied conviction level relative to the rest of each investor's book.
Key takeaways
8 hedge funds and family offices disclose a CVS position in their latest SEC 13F filing — combined $1.94B in market value. Of those, 2 are classified as value investors.
| # | Investor | Fund | Shares | Value | % of Portfolio | Filed |
|---|---|---|---|---|---|---|
| 1 | Christopher Davis | Davis Selected Advisers, LP | 11,865,916 | $1.23B | 5.27% | 2026-06-30 |
| 2 | Viking Global | Viking Global Investors LP | 3,663,361 | $379.0M | 1.08% | 2026-06-30 |
| 3 | Prem Watsa | Fairfax Financial Holdings Ltd | 2,712,000 | $280.5M | 10.63% | 2026-06-30 |
| 4 | Ray Dalio | Bridgewater Associates LP | 440,972 | $45.6M | 0.19% | 2026-06-30 |
| 5 | Mark Hillman | Hillman Capital Management Inc | 71,685 | $5.7M | 3.58% | 2025-12-31 |
| 6 | Matrix Asset Advisors | Matrix Asset Advisors Inc/NY | 6,175 | $490K | 0.04% | 2025-12-31 |
| 7 | Christopher Bloomstran | Semper Augustus Investments Group LLC | 499 | $40K | 0.01% | 2025-12-31 |
| 8 | Olstein Capital Management | Olstein Capital Management LP | 56,000 | $4K | 0.91% | 2025-12-31 |
As of the latest 13F window, 8 tracked superinvestors hold CVS. The largest disclosed position is Christopher Davis at $1.23B (5.3% of portfolio).
13F filings are due 45 days after each quarter end and capture long-equity positions held by U.S. institutional managers with $100M+ AUM. Use this page to see exactly who is buying CVS, how concentrated each position is, and the implied conviction level relative to the rest of each investor's book.
Key takeaways
